TTM
$11.78B
YoY change
+47.1%
5Y CAGR
+3.2%
Peak year (2025)
$10.68B
Cumulative operating income
$169.41B
Operating Income history chart for Amgen (AMGN) from 1985 to 2025
Latest: $10.68B
Operating Income growth chart for Amgen (AMGN) from 1985 to 2025
Latest: +47.1%
Operating Income history table for Amgen (AMGN) from 1985 to 2025
| 2025 | $10.68B | +47.1% | +$3.42B | ||
| 2024 | $7.26B | -8.1% | −$639.00M | ||
| 2023 | $7.90B | -17.4% | −$1.67B | ||
| 2022 | $9.57B | +25.2% | +$1.93B | ||
| 2021 | $7.64B | -16.4% | −$1.50B | ||
| 2020 | $9.14B | -5.5% | −$535.00M | ||
| 2019 | $9.67B | -5.7% | −$589.00M | ||
| 2018 | $10.26B | +2.9% | +$290.00M | ||
| 2017 | $9.97B | +1.8% | +$179.00M | ||
| 2016 | $9.79B | +15.6% | +$1.32B | ||
| 2015 | $8.47B | +36.8% | +$2.28B | ||
| 2014 | $6.19B | +5.5% | +$324.00M | ||
| 2013 | $5.87B | +5.2% | +$290.00M | ||
| 2012 | $5.58B | +29.3% | +$1.26B | ||
| 2011 | $4.31B | -22.2% | −$1.23B | ||
| 2010 | $5.54B | +0.7% | +$39.00M | ||
| 2009 | $5.51B | +5.6% | +$292.00M | ||
| 2008 | $5.21B | +31.0% | +$1.23B | ||
| 2007 | $3.98B | +3.6% | +$140.00M | ||
| 2006 | $3.84B | -20.8% | −$1.01B | ||
| 2005 | $4.85B | +44.8% | +$1.50B | ||
| 2004 | $3.35B | +8.3% | +$257.00M | ||
| 2003 | $3.09B | -493.8% | +$3.88B | ||
| 2002 | −$785.00M | -151.3% | −$2.32B | ||
| 2001 | $1.53B | +11.9% | +$163.10M | ||
| 2000 | $1.37B | +3.3% | +$43.10M | ||
| 1999 | $1.32B | +18.5% | +$206.60M | ||
| 1998 | $1.12B | +20.2% | +$188.10M | ||
| 1997 | $930.30M | +1.6% | +$14.30M | ||
| 1996 | $916.00M | +20.4% | +$155.20M | ||
| 1995 | $760.80M | +8.9% | +$62.30M | ||
| 1994 | $698.50M | +26.7% | +$147.30M | ||
| 1993 | $551.20M | +10.7% | +$53.10M | ||
| 1992 | $498.10M | +303.6% | +$374.70M | ||
| 1991 | $123.40M | +141.5% | +$72.30M | ||
| 1990 | $51.10M | — | — | ||
| 1988 | −$4.80M | -14.3% | +$800.00K | ||
| 1987 | −$5.60M | +300.0% | −$4.20M | ||
| 1986 | −$1.40M | +55.6% | −$500.00K | ||
| 1985 | −$900.00K | — | — |
- 2025$10.68B+47.1%
- 2024$7.26B-8.1%
- 2023$7.90B-17.4%
- 2022$9.57B+25.2%
- 2021$7.64B-16.4%
- 2020$9.14B-5.5%
- 2019$9.67B-5.7%
- 2018$10.26B+2.9%
- 2017$9.97B+1.8%
- 2016$9.79B+15.6%
- 2015$8.47B+36.8%
- 2014$6.19B+5.5%
- 2013$5.87B+5.2%
- 2012$5.58B+29.3%
- 2011$4.31B-22.2%
- 2010$5.54B+0.7%
- 2009$5.51B+5.6%
- 2008$5.21B+31.0%
- 2007$3.98B+3.6%
- 2006$3.84B-20.8%
- 2005$4.85B+44.8%
- 2004$3.35B+8.3%
- 2003$3.09B-493.8%
- 2002−$785.00M-151.3%
- 2001$1.53B+11.9%
- 2000$1.37B+3.3%
- 1999$1.32B+18.5%
- 1998$1.12B+20.2%
- 1997$930.30M+1.6%
- 1996$916.00M+20.4%
- 1995$760.80M+8.9%
- 1994$698.50M+26.7%
- 1993$551.20M+10.7%
- 1992$498.10M+303.6%
- 1991$123.40M+141.5%
- 1990$51.10M—
- 1988−$4.80M-14.3%
- 1987−$5.60M+300.0%
- 1986−$1.40M+55.6%
- 1985−$900.00K—
Operating Income values are taken from Amgen's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Amgen (AMGN)
According to Amgen's latest reported financial statements, the company's current operating income (TTM) is $11.78B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Amgen (AMGN) operating income totalled $10.68B – surged 47.1% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Amgen operating income compounded at +3.2% per year, with mixed annual results across the window.
The record annual operating income stands at $10.68B, reached in 2025; the historical low of −$785.00M was recorded in 2002.
Amgen Operating Income by Year
Amgen Operating Income 2025: $10.68B
Amgen posted operating income of $10.68B in 2025, surged 47.1% from 2024. This figure represents the highest annual value in the available history.
Amgen Operating Income 2024: $7.26B
In 2024, Amgen reported operating income of $7.26B, declined 8.1% below 2023.
Amgen Operating Income 2023: $7.90B
Amgen operating income in 2023 was $7.90B, declined 17.4% below 2022.
Amgen Operating Income 2022: $9.57B
2022's operating income for Amgen came in at $9.57B, grew 25.2% from 2021.
Amgen Operating Income 2021: $7.64B
Amgen operating income in 2021 was $7.64B.
See more financial history for Amgen (AMGN).
Sector peers by Operating Income
Healthcare peers of Amgen (AMGN), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $8.11B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
Frequently asked questions
Amgen (AMGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation